18. Nov. 2015 in PharmaTimes The National Institute for Health and Care Excellence has turned down Amgen’s Repatha – the world’s first approved PCSK9 inhibitor – as an option for people with high cholesterol and mixed dyslipidaemia. Key reasons for the negative decision were: (1) no long-term outcomes data and thus, the question of whether […]
